0 0.0076923076923077 0.0615384615384616 0.0461538461538462 -0.0615384615384616 -0.192307692307692 -0.0923076923076922 -0.353846153846154
Sign Up Today X
Thanks for submitting the form.
Stockreport

WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS [Canadian Business Journal (Canada)]

Moleculin Biotech, Inc. (MBRX)  More Company Research Source: Canadian Business Journal
Last moleculin biotech, inc. earnings: 8/16 05:35 pm Check Earnings Report
US:NASDAQ Investor Relations: moleculin.com/investors
VANCOUVER, British Columbia, March 19, 2020 (GLOBE NEWSWIRE) — WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) “Company” or “WPD” Moleculin Published research has revealed that viral replication can be highly dependent on specific monosaccharides and has demonstrated the effectiveness of a compound known as ‘2-DG,’ a dual decoy of glucose and mannose, in the treatment of certain viruses. Mariusz Olejniczak, CEO of WPD We are eager for testing to begin on our WP1122 drug for antiviral properties against viruses, including the prevalent Coronavirus. The in vivo research supporting the use of 2-DG as dual inhibitor of glycolysis and glycosylation to defeat viruses like Coronavirus through multiple effects critical to the progression of viral infection is promising We believe that during this difficult time, it is the responsibility of every biotech company to remain committed to research and test the entire drug portfolio to find alternative treatment for patients .” About WPD Pharmaceut [Read more]
IMPACT SNAPSHOT EVENT TIME: MBRX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
MBRX alerts
from News Quantified
MBRX
NEWS
MBRX
Earnings
MBRX
Analyst Actions
MBRX
SEC Filings
Stockreport

WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS [Canadian Business Journal (Canada)]

Moleculin Biotech, Inc.  (MBRX) 
More Company Research Source: Canadian Business Journal
Last moleculin biotech, inc. earnings: 8/16 05:35 pm Check Earnings Report
US:NASDAQ Investor Relations: moleculin.com/investors
VANCOUVER, British Columbia, March 19, 2020 (GLOBE NEWSWIRE) — WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) “Company” or “WPD” Moleculin Published research has revealed that viral replication can be highly dependent on specific monosaccharides and has demonstrated the effectiveness of a compound known as ‘2-DG,’ a dual decoy of glucose and mannose, in the treatment of certain viruses. Mariusz Olejniczak, CEO of WPD We are eager for testing to begin on our WP1122 drug for antiviral properties against viruses, including the prevalent Coronavirus. The in vivo research supporting the use of 2-DG as dual inhibitor of glycolysis and glycosylation to defeat viruses like Coronavirus through multiple effects critical to the progression of viral infection is promising We believe that during this difficult time, it is the responsibility of every biotech company to remain committed to research and test the entire drug portfolio to find alternative treatment for patients .” About WPD Pharmaceut [Read more]
IMPACT SNAPSHOT
EVENT TIME:
MBRX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS